During the corresponding time, Teva Pharmaceutical Industries Limited saw a revenue deteriorated by -0.81 % year on year, sequentially revenue grew by 3.99 %. While revenue at the Teva Pharmaceutical Industries Limited's corporate clients
Teva Pharmaceutical Industries Limited's Comment on Sales, Marketing and Customers
The company operates in the United States and Europe through three business segments. In the United States, it markets over 350 generic prescription products in various forms, primarily selling to retail drug chains, mail order distributors, and wholesalers. Its innovative medicines portfolio targets central nervous system disorders, respiratory conditions, oncology, and other areas, with products including AUSTEDO®, AUSTEDO XR®, AJOVY®, UZEDY®, COPAXONE®, TRUXIMA®, and BENDEKA®. The company also manages Anda, a distribution business that supplies generic, biosimilar, innovative medicines, and over-the-counter (OTC) products from Teva and other manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices. In Europe, the company is a leading pharmaceutical provider in generics, OTC, and biosimilars across the European Union, the United Kingdom, and other countries, offering a broad portfolio that includes global OTC brands such as SUDOCREM® and regional brands like NasenDuo®, DICLOX FORTE®, and OLFEN. Customers and markets referenced include Eagle Pharmaceuticals, Inc. and Teva.
News about Teva Pharmaceutical Industries Limited Contracts
In a groundbreaking presentation at Psych Congress Elevate 2025, Teva Pharmaceuticals has unveiled new data revealing significant rates of undertreated tardive dyskinesia (TD) among patients in long-term care (LTC) settings. This announcement is particularly timely and critical, as it brings to light the profound implications of inadequate diagnosis and treatment within this vulnerable population.Tardive dyskinesia, a condition characterized by involuntary, repetitive movements, often results from long-term use of antipsychotic medications. It poses not only a clinical challenge but also profoundly impacts the quality of life for countless individuals, particularly elderly patients residing in LTC facilities...
: Recent developments in the pharmaceutical landscape concerning autoimmune diseases like Ulcerative Colitis (UC) and Crohn’s Disease (CD) have spotlighted Duvakitug an innovative anti-TL1A monoclonal antibody co-developed by Teva Pharmaceuticals and Sanofi. The new Phase 2b study results presented at the European Crohn’s and Colitis Organisation (ECCO) 2025 conference demonstrate promising efficacy and safety profiles, underscoring Duvakitug’s best-in-class potential. This commentary reviews these findings and assesses their implications for both companies and the broader treatment landscape. The dual burden of Ulcerative Colitis and Crohn s Disease affects millions globally, presenting a pressing ...
News Tel Aviv, Israel, September 23, 2024 Teva Pharmaceutical Industries Ltd. announced promising results from a recent analysis at the European College of Neuropsychopharmacology (ECNP) annual congress in Milan, revealing that the treatment with deutetrabenazine has shown long-term efficacy in alleviating symptoms of Tardive Dyskinesia (TD) in European patients. This finding comes from the European cohort of the RIM-TD open-label extension (OLE) study, which monitored the condition of patients over a three-year period.Tardive Dyskinesia, a debilitating movement disorder often resulting from long-term use of antipsychotic medications, presents significant challenges for both patients and healthcare prov...
In the annals of modern pharmacotherapy, the pursuit of efficacious treatments for mental maladies remains a pressing venture, not least among them the formidable affliction of schizophrenia. It is with considerable contentment that this Journal reports on the commendable advancements proffered by Teva Pharmaceuticals, a prominent entity within the pharmaceutical industry, whose findings were recently unveiled during the esteemed 37th Annual Congress of the European College of Neuropsychopharmacology held in the illustrious city of Milan, Italy.On the twenty-first day of September in the year of our Lord two thousand and twenty-four, Teva Pharmaceuticals disclosed the results of the Phase 3 Subcutaneous Olan...
Teva Pharmaceutical Industries Limited’s Comment on Sales, Marketing and Customers
The company operates in the United States and Europe through three business segments. In the United States, it markets over 350 generic prescription products in various forms, primarily selling to retail drug chains, mail order distributors, and wholesalers. Its innovative medicines portfolio targets central nervous system disorders, respiratory conditions, oncology, and other areas, with products including AUSTEDO®, AUSTEDO XR®, AJOVY®, UZEDY®, COPAXONE®, TRUXIMA®, and BENDEKA®. The company also manages Anda, a distribution business that supplies generic, biosimilar, innovative medicines, and over-the-counter (OTC) products from Teva and other manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices. In Europe, the company is a leading pharmaceutical provider in generics, OTC, and biosimilars across the European Union, the United Kingdom, and other countries, offering a broad portfolio that includes global OTC brands such as SUDOCREM® and regional brands like NasenDuo®, DICLOX FORTE®, and OLFEN. Customers and markets referenced include Eagle Pharmaceuticals, Inc. and Teva.
Sources:
Teva Pharmaceutical Industries Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Teva Pharmaceutical Industries Limited’s corporate clients.
For your research, we’ve provided 9 tables on Teva Pharmaceutical Industries Limited corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
78.13 %